A case of STING-associated vasculopathy with onset in infancy highlighting the pathogenetic role of interferon regulatory factor 5

Clicks: 21
ID: 333129
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #88 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives To elucidate the pathophysiology of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI), we evaluated interferon-stimulated gene (ISG) expression and nuclear translocation of interferon regulatory factors 3 and 5 (IRF3 and IRF5) in patient-derived cells before and after Janus kinase (JAK) inhibitor treatment. Methods A 3-year-old girl presenting with refractory eczema, polyarthritis, and interstitial lung disease (ILD) was confirmed to have SAVI. Baricitinib, a JAK1/2 inhibitor, was initiated for refractory ILD, and peripheral blood samples were analysed before and 4 months after baricitinib initiation. Expression of representative ISGs (IFI27, MX1, and OAS1) was quantified by reverse-transcription quantitative polymerase chain reaction. Nuclear localization of IRF3 and IRF5 was examined in sorted monocytes and B cells using confocal microscopy after intracellular staining. Activation was quantified by the nuclear-to-cytoplasmic mean fluorescence intensity ratio. Results ISG expression was markedly elevated at baseline and decreased to levels comparable to those in a healthy control subject after 4 months of treatment. IRF3 localization remained unchanged, whereas IRF5 showed pronounced nuclear enrichment in monocytes at baseline, an effect that diminished after treatment. This reduction paralleled clinical improvement, including resolution of lung involvement and rash, and seroreversion of autoantibodies. Conclusion IRF5 activation may sustain chronic inflammation in SAVI independently of IRF3. The observed reduction in IRF5 nuclear translocation paralleled the improvement in disease activity, suggesting that targeting IRF5 may help suppress inflammatory processes not adequately controlled by existing treatments.
Reference Key
openalex_W7223043810 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors 裕二 神山, Tatsuma Ban, Go R Sato, Masako Kikuchi, Tomo Nozawa, Seira Hattori, Kenichi Nishimura, Tomohiko Tamura, Shuichi Ito
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag562
URL
https://doi.org/10.1093/rheumatology/keag562
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.